Last reviewed · How we verify
co.don chondrosphere® — Competitive Intelligence Brief
phase 3
Cell-based therapy
Orthopedics
Small molecule
Live · refreshed every 30 min
Target snapshot
co.don chondrosphere® (co.don chondrosphere®) — co.don AG. co.don chondrosphere is a cell-based therapy that utilizes autologous chondrocytes to repair cartilage defects.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| co.don chondrosphere® TARGET | co.don chondrosphere® | co.don AG | phase 3 | Cell-based therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Cell-based therapy class)
- State-Financed Health Facility "Samara Regional Medical Center Dinasty" · 1 drug in this class
- co.don AG · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- co.don chondrosphere® CI watch — RSS
- co.don chondrosphere® CI watch — Atom
- co.don chondrosphere® CI watch — JSON
- co.don chondrosphere® alone — RSS
- Whole Cell-based therapy class — RSS
Cite this brief
Drug Landscape (2026). co.don chondrosphere® — Competitive Intelligence Brief. https://druglandscape.com/ci/co-don-chondrosphere. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing